Loading company
Satellos Bioscience Inc.
MSLE · Nasdaq · ·
$8.60-1.6%Sep 29 close
- 1M
- -0.7%
- 6M
- +45.5%
MSLE · Nasdaq · ·
$8.60-1.6%Sep 29 close
From the company’s own 6-K filing.
“Our progress in the second quarter demonstrates our commitment and ability to effectively deliver on our promises to the Duchenne community,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Satellos Bioscience Inc. filed on August 13, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Satellos Bioscience Inc. has no earnings call transcript available.